

# PATENT COOPERATION TREATY

From the  
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

**BARKER BRETTELL**

To:

BARKER, Brettell  
138 Hagley Road  
Edgbaston  
Birmingham B16 9PW  
GRANDE BRETAGNE

22 SEP 2004

**RECEIVED**

**PCT**

**WRITTEN OPINION**  
(PCT Rule 66)

		Date of mailing (day/month/year)	20.09.2004
Applicant's or agent's file reference CDK2146		REPLY DUE	<b>within 3 month(s)</b> from the above date of mailing
International application No. PCT/GB 03/05544	International filing date (day/month/year) 18.12.2003	Priority date (day/month/year) 24.12.2002	<i>SEARCHED</i> <i>INDEXED</i> <i>FILED</i>
International Patent Classification (IPC) or both national classification and IPC C07F9/24			
Applicant RHODIA CONSUMER SPECIALTIES LIMITED et al.			

1. This written opinion is the **second** drawn up by this International Preliminary Examining Authority.
2. This opinion contains indications relating to the following items:
  - I  Basis of the opinion
  - II  Priority
  - III  Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
  - IV  Lack of unity of invention
  - V  Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
  - VI  Certain documents cited
  - VII  Certain defects in the international application
  - VIII  Certain observations on the international application
3. The applicant is hereby invited to reply to this opinion.
 

**When?** See the time limit indicated above. The applicant may, before the expiration of that time limit, request this Authority to grant an extension, see Rule 66.2(d).

**How?** By submitting a written reply, accompanied, where appropriate, by amendments, according to Rule 66.3. For the form and the language of the amendments, see Rules 66.8 and 66.9.

**Also:** For an additional opportunity to submit amendments, see Rule 66.4. For the examiner's obligation to consider amendments and/or arguments, see Rule 66.4 bis. For an informal communication with the examiner, see Rule 66.6.

If no reply is filed, the international preliminary examination report will be established on the basis of this opinion.
4. The final date by which the international preliminary examination report must be established according to Rule 69.2 is: 24.04.2005

RECORDS DEPT.  
SEEN BY: *TM*  
AGENT: *CDK/PFT*

Name and mailing address of the international preliminary examining authority:   European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized Officer  Elliott, A
	Formalities officer (incl. extension of time limits)  Ullrich, J Telephone No. +49 89 2399-8048



**I. Basis of the opinion**

1. With regard to the **elements** of the international application (*Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this opinion as "originally filed"*):

**Description, Pages**

1-5 as originally filed

**Claims, Numbers**

1-19 as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- the language of publication of the international application (under Rule 48.3(b)).
- the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- contained in the international application in written form.
- filed together with the international application in computer readable form.
- furnished subsequently to this Authority in written form.
- furnished subsequently to this Authority in computer readable form.
- The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- the description, pages:
- the claims, Nos.:
- the drawings, sheets:

5.  This opinion has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)).

6. Additional observations, if necessary:

**III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability**

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been and will not be examined in respect of:

- the entire international application,
- claims Nos. 17-19  
because:
- the said international application, or the said claims Nos. relate to the following subject matter which does not require an international preliminary examination (specify):
- the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):
- the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.
- no international search report has been established for the said claims Nos. 17-19
2. A written opinion cannot be drawn due to the failure of the nucleotide and/or amino acid sequence listing to comply with the Standard provided for in Annex C of the Administrative Instructions:
- the written form has not been furnished or does not comply with the Standard.
- the computer readable form has not been furnished or does not comply with the Standard.

**V. Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

1. Statement

Novelty (N)	Claims	1-13 : yes Claims 14-16 : no Claims 17-19 : no opinion
Inventive step (IS)	Claims	1-13 : yes Claims 14-16 : no Claims 17-19 : no opinion
Industrial applicability (IA)	Claims	1-16 : yes Claims 17-19 : no opinion

2. Citations and explanations

**see separate sheet**

**VI. Certain documents cited**

1. Certain published documents (Rule 70.10)

and / or

2. Non-written disclosures (Rule 70.9)

**see separate sheet**

The application relates to a process for producing a phosphorodiamidite by reacting a phosphorus trihalide with a dialkylamine in a polar solvent to form an intermediate and subsequently reacting the intermediate with a hydroxyalkyl compound and a dialkyl amine in the presence of a non-polar co-solvent. Also claimed is the phosphorodiamidite of formula (I) and the use thereof in the synthesis of oligonucleotides.

The following documents are referred to in this opinion:

- D1: WO 03/106468 A (RHODIA) 24 December 2003 (2003-12-24)
- D2: WO 03/087130 A (ISIS PHARMACEUTICALS INC (US)) 23 October 2003 (2003-10-23)
- D3: PATENT ABSTRACTS OF JAPAN vol. 012, no. 075 (C-480), 9 March 1988 (1988-03-09) & JP 62 212395 A (NIPPON ZEON CO LTD), 18 September 1987 (1987-09-18)
- D4: HAMAMOTO S TAKAKU H: 'New Approach to the Synthesis of Deoxyribonucleoside Phosphoramidite Derivatives' CHEMISTRY LETTERS, CHEMICAL SOCIETY OF JAPAN. TOKYO, JP, vol. 8, 1986, pages 1401-1404, XP002902766 ISSN: 0366-7022
- D5: PFLEIDERER W ET AL: 'Inhibition of HIV-1 replication and activation of RNase L by phosphorothioate/ phosphodiester 2',5'-oligoadenylate derivatives' JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 270, no. 11, 17 March 1995 (1995-03-17), pages 5963-5978, XP002079044 ISSN: 0021-9258
- D6: HOULLA D ET AL: 'PREPARATIONS ET QUELQUES PROPRIETES DE COMPOSES CONTENANT LA LIAISON PHOSPHORE TRIVALENT-AZOTE' BULLETIN DE LA SOCIETE CHIMIQUE DE FRANCE, SOCIETE FRANCAISE DE CHIMIE. PARIS, FR, 1965, pages 2368-2373, XP009028565 ISSN: 0037-8968
- D7: 'FLUKA CHEMIKA, BIOCHEMIKA UND ANALYTIKA KATALOG 1997/98' 1997 , FLUKA CHEMIE AG XP002277275

**III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability**

No opinion is given as to the patentability of claims 17-19, no search report having been drawn up therefor.

**V Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step and industrial applicability; citations and explanations supporting such statement**

The subject-matter of claims 1-13 would appear to be novel in the light of the prior art as none of the prior art documents discloses the use of two different non-miscible solvents for the different steps of the presently-claimed process. D3 describes the reaction between a phosphorus trihalide and a secondary amine and the subsequent reaction of the bisaminomonohalogenophosphine with an alcohol (no details of the solvent system used are given in the abstract for D3). D4 discloses the reaction of  $\text{PCl}_3$  with diisopropylamine in ether to firstly produce bis(diisopropylamine)chlorophosphine which is further reacted again in ether with 2-pyridylethanol. D5 exemplifies the more typical synthesis wherein  $\text{PCl}_3$  is first reacted with the alcohol and then with the amine (cf. the preparation of compound (3) in

column 1 on page 5964 and the synthesis of compound (27) in column 1 on page 5966). D6 in the experimental part thereof (page 2370, columns 1 & 2) shows firstly the preparation of tris(dialkylamino)phosphines and then their reaction with an alcohol to produce the phosphorodiamidites.

On the other hand the subject-matter of claims **14-16** would not appear to be new. It should firstly be pointed out that a compound prepared by a different synthetic route to that employed in the past is still the same compound. Document D7 which is an extract from Fluka's chemicals, biochemicals and analytical reagents catalogue from 1997/1998 contains reference to the specific compound of claim 15 and even states its use as being for nucleotide synthesis (cf. references cited in D7). On the basis of D7 alone claims 14-16 lack novelty. It should further be added that, although the process of claims 1-13 would appear to produce a purer product than achieved with prior art syntheses, the fact that the products from these prior art syntheses would have been further purified before their use means that a product of the same purity as that presently achieved was clearly known in the art.

Claims **1-13** would, on the basis of the fact that the process provides a purer product compared with the prior art processes, appear to be based on inventive merit.

Claims **14-16**, lacking novelty, correspondingly lack inventive step.

**Other matters:**

1. The applicant has not cited any prior art in the application. D3-D6 should therefore be mentioned in the description (Rule 5.1(a)(ii) PCT).
2. **Certain documents cited**

D1, a PCT application published after the filing date of the present application, is not to be considered as prior art according to Rule 64.3 PCT.

D1 is an application providing a method for producing cyanoalkyl tetraalkylphosphoramidites by reacting phosphorus trihalide with a cyano-containing agent to form cyanoalkylphosphordihalidite which is reacted with a dialkylamine to form the cyanoalkyl tetraalkylphosphoramidite and amine hydrochloride byproduct at least a portion of which is in the form of a precipitate. The amine precipitate is removed by filtration and the filtrate is further treated with a substance capable of

removing any dissolved amine hydrohalide.

D2, published in the priority interval of the present application, is likewise not to be considered as prior art according to Rule 64.3 PCT.

D2 provides a process for purifying a phosphorodiamidite by solvent extraction.

Neither D1 nor D2 would appear to affect the positive opinion expressed above concerning claims 1-13.